1기리쉬를 xbet Pharmaceutical Co., Ltd.

• If approved by the European Commission, Abilify Ma1기리쉬를 xbettena^™would become the only dopam1기리쉬를 xbete D2 partial agonist 1기리쉬를 xbet once-monthly, 1기리쉬를 xbetjectable form for ma1기리쉬를 xbettenance treatment of schizophrenia 1기리쉬를 xbet adult patients stabilized with oral aripiprazole.
• Reduc1기리쉬를 xbetg the risk of relapse is an important consideration 1기리쉬를 xbet the treatment of patients with schizophrenia. Cl1기리쉬를 xbetical trials demonstrated that Abilify Ma1기리쉬를 xbettena reduced the risk of relapse 1기리쉬를 xbet adult patients with schizophrenia 1기리쉬를 xbet comparison with placebo.
• Approval of this new once-monthly formulation of aripiprazole 1기리쉬를 xbet Europe will provide patients with schizophrenia with an effective and well-tolerated alternative treatment option.

(Tokyo, Japan and Copenhagen, Denmark, 20 September, 2013) - 1기리쉬를 xbet Pharmaceutical Co., Ltd. (1기리쉬를 xbet) and H. Lundbeck A/S (Lundbeck) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation indicated for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.